午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook
Chinese English Germany Korean

AnaSpec Inc 企業(yè)の連絡先情報

名前:AnaSpec Inc
電話番號:180-04525530
電子メール:service@anaspec.com
國籍:China
ウェブサイト:www.anaspec.com
商品の合計數(shù):1805
11 12 13 14 15 16 17 18 19

製品カタログ

SARS-CoV-2 Spike receptor binding domain, RBD (336-347) - Lys(Biotin-LC) - 0.1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (348-357)- Lys(Biotin-LC) - 0.1 mg
Proapoptotic Peptide, (klaklak)2, 5-FAM-labeled - 1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (523-541) - 0.5 mg
pp60(v-SRC) Autophosphorylation Site, Phosphorylated - 1 mg
QXL? 490 acid - 10 mg
Proinsulin C-peptide (55-87), porcine - 0.5 mg28152-90-1C142H239N47O46
Renin FRET Substrate, R-E(EDANS)--K(Dabcyl) - 1 mg791068-69-4C109H156N32O21S
Protease-Activated Receptor-3, PAR-3 Agonist, amide - 1 mg261521-21-5C25H36N8O8
Pyrrhocoricin - 1 mg156548-23-1C113H179N33O34
Protein A-HiLyte Fluor 555 Conjugate - 1 mg
SARS - CoV - 2 Spike RBM (receptor binding motif), 480 - 496 - 0.5 mg
Prostatic Acid Phosphatase (248-286), PAP (248-286) - 1 mg
Protein A-HiLyte Fluor 488 Conjugate - 1 mg
Protein A-HiLyte Fluor 750 Conjugate - 1 mg
Protein A-Biotin Conjugate - 5 mg
QXL? 570 C2 maleimide - 5 mg
SARS-CoV-2 Spike receptor binding domain, RBD (352-365) - Lys(Biotin-LC) - 0.1 mg
Protease-Activated Receptor-1, PAR-1 Agonist 2, amide - 1 mg
Protease-Activated Receptor-3, PAR-3 (1-6), human - 1 mg1872435-09-0C29H46N10O7
Protease-Activated Receptor-2, PAR-2 Agonist, amide - 1 mg2-フロイル-LIGRLO-アミド729589-58-6C36H63N11O8
Rat Renin, recombinant - 20 μg
SARS-CoV Peptide Antigen Negative control - 1mg NET peptide
RGD-4C - 5 mg
S6 Kinase Substrate (229-239), Amide, Biotinalyted - 1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (513-520) - 0.5 mg
Recombinant mouse MOG (1-125)
Prosaptide TX14(A)プロサプチドD1196391-82-9C69H110N16O26
S6 Kinase Substrate (229-239)C54H104N24O14
PrP (106-126), prion protein - 1 mgプリオンタンパク (106-126) (ヒト)148439-49-0C80H138N26O24S2
Pluronic? F-127 Cell Culture Tested - 10 gポロキサレン9003-11-6(C3H6O.C2H4O)x
SAMS Peptide [HMRSAMSGLHLVKRR-NH2] - 5 mg
PSTi8, 1mg
pro-NPY peptide (34-43), human - 0.1 mg
Protegrin-1 (PG-1), amide
Renin FRET substrate, Dabcyl/EDANS - 1 mg142988-22-5C90H120N22O16S
Quinine sulfate Fluorescence Reference Standard - 100 mg硫酸キニーネ二水和物6119-70-6C20H26N2O6S
Resorufin -D-Galactopyranoside - 25 mgレソルフィンβ-D-ガラクトピラノシド95079-19-9C18H17NO8
Protease-Activated Receptor-4, PAR-4 Antagonist, amide - 1 mg327177-34-4C40H49N7O7
R-PE (R-Phycoerythrin) - 1 mg
Renin Inhibitor Peptide, WFML Peptide, rat - 1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) - Lys(Biotin-LC) - 0.1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (336-347) - 0.5 mg
Protein A-HiLyte Fluor 647 Conjugate - 1 mg
RS domain derived peptide - 1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (319-335) -Lys(Biotin-LC) - 0.1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (513-520) - Lys(Biotin-LC) - 0.1 mg
Rev4
Proadrenomedullin N-term peptide, PAMP (1-20) - 5 mgPAMP, ヒト150238-87-2C112H178N36O27
Renin Substrate, Angiotensinogen (1-14), human - 1 mg104180-23-6C83H122N24O19
Pramlintide, Acetate [Pro25, 28, 29]-Amylin(1-37), human, Amide - 1 mg196078-30-5C173H273N51O56S2
QXL? 570 acid, SE - 5 mg
SARS - CoV - 2 Spike RBM (receptor binding motif), 438 - 458 - 0.5 mg
SARS-CoV-2 Spike receptor binding domain, RBD (395-430) - Lys(Biotin-LC) - 0.1 mg
SARS-CoV T-cell Peptide Antigens Set - 0.25 mg Net
Protease-Activated Receptor-1, PAR-1 Agonist - 1 mg
Renin FRET Substrate (5-FAM/QXL? 520) - 0.1 mg
Pluronic? F-127, 10 % solution in water - 100 ml
Proapoptotic Peptide, (klaklak)2 - 1 mg
Renin Substrate, Angiotensinogen (1-14), rat - 1 mg110200-37-8C89H123N21O21
QXL? 670 acid, SE - 5 mg
pVEC (Cadherin-5) - 1 mg
PUMA BH3 - 1 mg
Recombinant human MOG (1-125)
SAMs peptide, FAM labeled - 1 mg
Protease-Activated Receptor-1, PAR-1 Antagonist 1 - 1 mgYFLLRNPトリフルオロ酢酸塩149440-16-4C45H67N11O10
Rhod-2, AM UltraPure Grade - 1 mg145037-81-6C52H59N4O19.Br
Protease-Activated Receptor-2, PAR-2 Agonist 2, amide - 5 mgPAR-2 (1-6) アミド (ヒト)190383-13-2C28H54N8O7
Proteases Substrate, Fluorogenic, (Z-R)2Rh1102HCl - 5 mg
Poly-gamma-D-Glutamic Acid Construct - 1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) - 0.5 mg
S3 Fragment, ADF/cofilin, LIMK1 substrate - 1 mg
Propidium iodide, 1.0 mg/mL solution in water - 10 ml3,8-ジアミノ-5-[3-(ジエチルメチルアミニオ)プロピル]-6-フェニルフェナントリジン-5-イウム·ヨージド25535-16-4C27H34IN4+
Prodan [6-Propionyl-2-dimethylaminonaphthalene] - 25 mg2-(ジメチルアミノ)-6-プロピオニルナフタレン70504-01-7C15H17NO
SARS-CoV-2 Spike receptor binding domain, RBD (352-365) - 0.5 mg
PMAP-23
Proinsulin C-peptide (55-89), human - 0.5 mgプロインスリン C-ペプチド(55-89) ヒト11097-48-6C153H259N49O52
Protease-Activated Receptor-4, PAR-4 Agonist, amideGly-Tyr-Pro-Gly-Lys-Phe-OH352017-71-1C34H48N8O7
Rhodopsin Epitope Tag - 5 mg
Rabies Virus Glycoprotein (RVG) - 1 mg
Renin FRET Substrate (5-FAM/QXL? 520), rat - 0.1 mg
QXL? 570 acid - 10 mg
Protease-Activated Receptor-1, PAR-1 Antagonist 2, amide - 1 mg
SARS - CoV - 2 Spike RBM (receptor binding motif), 500 - 509 - 0.5 mg
RGDS - 5 mgH-ARG-GLY-ASP-SER-OH91037-65-9C15H27N7O8
SARS-CoV-2 Spike receptor binding domain, RBD (319-335) - 0.5 mg
QXL? 490 acid, SE - 5 mg
SARS-CoV Peptide Antigen I - 1mg NET peptide
Protease-Activated Receptor-1, PAR-1 Agonist 3, amide - 1 mg
Recombinant rat MOG (1-125)
RH414 - 5 mg4-[4-[4-(ジエチルアミノ)フェニル]-1,3-ブタジエニル]-1-[3-(トリエチルアミニオ)プロピル]ピリジニウム161433-30-3C28H43Br2N3
Protease-Activated Receptor-1, PAR-1 Agonist 1, amide - 5 mg
SARS-CoV-2 Spike receptor binding domain, RBD (523-541) - Lys(Biotin-LC) - 0.1 mg
SARS-CoV-2 Spike receptor binding domain, RBD (395-430) - 0.5 mg
SARS - CoV - 2 Spike RBM (receptor binding motif), 450 - 473 - 0.5 mg
SARS-CoV Peptide Antigen Positive control - 1mg NET peptide
SARS-CoV-2 Spike receptor binding domain, RBD (348-357) - 0.5 mg
Protease-Activated Receptor-4, PAR-4 Agonist 3, amide, murine - 1 mg245443-52-1C33H46N8O7
Ryanodine receptor 1 (RyR1) (3614-3643), Calmodulin Binding Peptide (CaMBP) - 1 mg
Pluronic? F-127, 20 % solution in DMSO - 10 ml
11 12 13 14 15 16 17 18 19
Copyright 2017 ? ChemicalBook. All rights reserved